JP2021514007A5 - - Google Patents
Info
- Publication number
- JP2021514007A5 JP2021514007A5 JP2020544852A JP2020544852A JP2021514007A5 JP 2021514007 A5 JP2021514007 A5 JP 2021514007A5 JP 2020544852 A JP2020544852 A JP 2020544852A JP 2020544852 A JP2020544852 A JP 2020544852A JP 2021514007 A5 JP2021514007 A5 JP 2021514007A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- compound
- acceptable salt
- leukemia
- lymphoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023096315A JP7521070B2 (ja) | 2018-02-27 | 2023-06-12 | Ｔｃｒ－ｎｃｋ相互作用の阻害剤としてのクロメン誘導体 |
| JP2024111017A JP2024138421A (ja) | 2018-02-27 | 2024-07-10 | Ｔｃｒ－ｎｃｋ相互作用の阻害剤としてのクロメン誘導体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862635834P | 2018-02-27 | 2018-02-27 | |
| US62/635,834 | 2018-02-27 | ||
| PCT/US2019/019856 WO2019169001A1 (en) | 2018-02-27 | 2019-02-27 | Chromene derivatives as inhibitors of tcr-nck interaction |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023096315A Division JP7521070B2 (ja) | 2018-02-27 | 2023-06-12 | Ｔｃｒ－ｎｃｋ相互作用の阻害剤としてのクロメン誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021514007A JP2021514007A (ja) | 2021-06-03 |
| JP2021514007A5 true JP2021514007A5 (https=) | 2022-03-02 |
| JP7317032B2 JP7317032B2 (ja) | 2023-07-28 |
Family
ID=65724589
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020544852A Active JP7317032B2 (ja) | 2018-02-27 | 2019-02-27 | Ｔｃｒ－ｎｃｋ相互作用の阻害剤としてのクロメン誘導体 |
| JP2023096315A Active JP7521070B2 (ja) | 2018-02-27 | 2023-06-12 | Ｔｃｒ－ｎｃｋ相互作用の阻害剤としてのクロメン誘導体 |
| JP2024111017A Pending JP2024138421A (ja) | 2018-02-27 | 2024-07-10 | Ｔｃｒ－ｎｃｋ相互作用の阻害剤としてのクロメン誘導体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023096315A Active JP7521070B2 (ja) | 2018-02-27 | 2023-06-12 | Ｔｃｒ－ｎｃｋ相互作用の阻害剤としてのクロメン誘導体 |
| JP2024111017A Pending JP2024138421A (ja) | 2018-02-27 | 2024-07-10 | Ｔｃｒ－ｎｃｋ相互作用の阻害剤としてのクロメン誘導体 |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US10696663B2 (https=) |
| EP (1) | EP3759086A1 (https=) |
| JP (3) | JP7317032B2 (https=) |
| KR (2) | KR20260028873A (https=) |
| CN (2) | CN112189009B (https=) |
| AU (2) | AU2019229258B2 (https=) |
| BR (1) | BR112020017386A2 (https=) |
| CA (1) | CA3091202A1 (https=) |
| CO (1) | CO2020010537A2 (https=) |
| EA (1) | EA202091742A1 (https=) |
| IL (2) | IL301120B2 (https=) |
| MX (2) | MX2020008814A (https=) |
| PH (1) | PH12020500638A1 (https=) |
| SG (1) | SG11202008067QA (https=) |
| WO (1) | WO2019169001A1 (https=) |
| ZA (1) | ZA202310843B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3759086A1 (en) | 2018-02-27 | 2021-01-06 | Artax Biopharma Inc. | Chromene derivatives as inhibitors of tcr-nck interaction |
| WO2025137442A1 (en) * | 2023-12-22 | 2025-06-26 | Artax Biopharma Inc. | SOLID AND SALT FORMS OF TCR-NcK MODULATORS AND USES THEREOF |
| WO2025255109A1 (en) * | 2024-06-03 | 2025-12-11 | Artax Biopharma Inc. | Combination of a chromene derivative tcr inhibitor and a pde4 inhibitor |
| WO2025255093A1 (en) * | 2024-06-03 | 2025-12-11 | Artax Biopharma Inc. | Combination of a car-t therapy and a chromene derivative tcr inhibitor |
| WO2025255091A1 (en) * | 2024-06-03 | 2025-12-11 | Artax Biopharma Inc. | Combination of a chromene derivative tcr inhibitor and a jak inhibitor |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| FR2772761B1 (fr) * | 1997-12-23 | 2000-05-26 | Lipha | Nouveaux derives de n-phenylamide et n-pyridylamide, leur procede de preparation et compositions pharmaceutiques les contenant |
| ATE260269T1 (de) | 1999-11-05 | 2004-03-15 | Cytovia Inc | Substituierte 4h-chromene und ähnliche verbindungen als kaspasis aktivatoren und apoptosis induktoren und deren verwendung |
| DE60037345T2 (de) | 1999-12-10 | 2008-11-13 | Pfizer Products Inc., Groton | Pyrrolo(2,3-d)pyrimidin-Verbindungen |
| AU2001278980A1 (en) | 2000-07-21 | 2002-02-05 | Chugai Seiyaku Kabushiki Kaisha | Coumarin derivatives useful as tnfalpha inhibitors |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| DE60217322T2 (de) | 2001-04-27 | 2007-10-04 | Zenyaku Kogyo K.K. | Heterocyclische verbindung und antitumormittel, das diese als wirkstoff enthält |
| WO2002092076A1 (en) | 2001-05-16 | 2002-11-21 | Cytovia, Inc. | Substituted coumarins and quinolines as caspases activators |
| PL374215A1 (en) * | 2001-08-11 | 2005-10-03 | Bristol-Myers Squibb Pharma Company | Selective estrogen receptor modulators |
| WO2003062272A1 (es) | 2002-01-24 | 2003-07-31 | Consejo Superior De Investigaciones Científicas | Nueva estrategia moduladora de la activacion de los linfocitos t basada en la regulación de la interaccion cd3e- nck. |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| EP1513515A2 (en) | 2002-05-16 | 2005-03-16 | Cytovia, Inc. | Substituted 4h-chromenes, 2h-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| PT1536827E (pt) | 2002-08-14 | 2009-03-20 | Silence Therapeutics Ag | Utilização de proteína cinase n beta |
| AU2004228668B2 (en) | 2003-04-03 | 2011-10-27 | Park Funding, Llc | PI-3 kinase inhibitor prodrugs |
| ES2382377T3 (es) | 2003-05-30 | 2012-06-07 | Gemin X Pharmaceuticals Canada Inc. | Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer |
| EP1692153A4 (en) | 2003-07-03 | 2007-03-21 | Univ Pennsylvania | INHIBITION OF EXPRESSION OF SYK-KINASE |
| WO2005113556A1 (en) | 2004-05-13 | 2005-12-01 | Icos Corporation | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
| AU2006206458B2 (en) | 2005-01-19 | 2012-10-25 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| PL1888550T3 (pl) | 2005-05-12 | 2014-12-31 | Abbvie Bahamas Ltd | Promotory apoptozy |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
| US7989622B2 (en) | 2005-10-07 | 2011-08-02 | Exelixis, Inc. | Phosphatidylinositol 3-kinase inhibitors and methods of their use |
| JP5191391B2 (ja) | 2005-11-01 | 2013-05-08 | ターゲジェン インコーポレーティッド | キナーゼのビ−アリールメタ−ピリミジン阻害剤 |
| SG10202003901UA (en) | 2005-12-13 | 2020-05-28 | Incyte Holdings Corp | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| GB0607389D0 (en) | 2006-04-12 | 2006-05-24 | Novartis Ag | Organic compounds |
| WO2007129161A2 (en) | 2006-04-26 | 2007-11-15 | F. Hoffmann-La Roche Ag | Thieno [3, 2-d] pyrimidine derivative useful as pi3k inhibitor |
| DK2526933T3 (en) | 2006-09-22 | 2015-05-18 | Pharmacyclics Inc | Inhibitors of Bruton's tyrosine kinase |
| KR101566840B1 (ko) | 2007-03-12 | 2015-11-06 | 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 | 페닐 아미노 피리미딘 화합물 및 이의 용도 |
| WO2008118802A1 (en) | 2007-03-23 | 2008-10-02 | Regents Of The University Of Minnesota | Therapeutic compounds |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| JP5569857B2 (ja) * | 2007-08-10 | 2014-08-13 | アステラス製薬株式会社 | 二環式アシルグアニジン誘導体 |
| HUE029767T2 (en) | 2008-03-11 | 2017-04-28 | Incyte Holdings Corp | JAK inhibitor azetidine and cyclobutane derivatives |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| ES2331451B1 (es) | 2008-06-30 | 2010-10-21 | Consejo Superior De Investigaciones Cientificas (Csic) | Inmunosupresor basado en la interrupcion de la interaccion tcr-nck. |
| EP2326634B1 (en) | 2008-07-16 | 2014-11-05 | Bristol-Myers Squibb Company | Chromene modulators of chemokine receptor activity |
| ES2334318B2 (es) | 2008-09-05 | 2011-11-28 | Universidad Politécnica de Madrid | Sistema de deteccion optica para bio-ensayos de alta sensibilidad sinmarcado. |
| MX2011005954A (es) | 2008-12-05 | 2011-10-11 | Astellas Pharma Inc | Compuesto de 2h-cromeno y su derivado. |
| ES2379242B1 (es) * | 2010-09-28 | 2013-03-04 | Consejo Superior De Investigaciones Científicas (Csic) | Derivados de cromeno. |
| US20140171445A1 (en) * | 2011-08-04 | 2014-06-19 | The Usa, As Represented By The Secretary, Department Of Health And Human Services | Treatment and prevention of diseases mediated by microorganisms via drug-mediated manipulation of the eicosanoid balance |
| EP2693164A1 (en) | 2012-08-03 | 2014-02-05 | Universidad Politécnica de Madrid | Interferometric detection method |
| ES2534318B1 (es) * | 2013-10-18 | 2016-01-28 | Artax Biopharma Inc. | Derivados de cromeno sustituidos por alcóxido como inhibidores de la interacción TCR-Nck |
| ES2534336B1 (es) * | 2013-10-18 | 2016-01-28 | Artax Biopharma Inc. | Derivados de cromeno como inhibidores de la interacción TCR-Nck |
| US9968604B2 (en) * | 2015-04-16 | 2018-05-15 | Chiesi Farmaceutici S.P.A. | Chromene derivatives as phoshoinositide 3-kinases inhibitors |
| CN104844471B (zh) * | 2015-04-21 | 2017-05-03 | 苏州远智医药科技有限公司 | 一种作为dor受体拮抗剂的化合物 |
| EP3759086A1 (en) | 2018-02-27 | 2021-01-06 | Artax Biopharma Inc. | Chromene derivatives as inhibitors of tcr-nck interaction |
-
2019
- 2019-02-27 EP EP19710272.6A patent/EP3759086A1/en active Pending
- 2019-02-27 EA EA202091742A patent/EA202091742A1/ru unknown
- 2019-02-27 AU AU2019229258A patent/AU2019229258B2/en active Active
- 2019-02-27 CN CN201980020981.7A patent/CN112189009B/zh active Active
- 2019-02-27 WO PCT/US2019/019856 patent/WO2019169001A1/en not_active Ceased
- 2019-02-27 MX MX2020008814A patent/MX2020008814A/es unknown
- 2019-02-27 IL IL301120A patent/IL301120B2/en unknown
- 2019-02-27 CA CA3091202A patent/CA3091202A1/en active Pending
- 2019-02-27 KR KR1020267003633A patent/KR20260028873A/ko active Pending
- 2019-02-27 JP JP2020544852A patent/JP7317032B2/ja active Active
- 2019-02-27 BR BR112020017386-0A patent/BR112020017386A2/pt unknown
- 2019-02-27 US US16/287,771 patent/US10696663B2/en active Active
- 2019-02-27 CN CN202311248809.1A patent/CN117304157A/zh active Pending
- 2019-02-27 SG SG11202008067QA patent/SG11202008067QA/en unknown
- 2019-02-27 KR KR1020207027883A patent/KR102924679B1/ko active Active
-
2020
- 2020-05-20 US US16/878,842 patent/US11008310B2/en active Active
- 2020-08-20 PH PH12020500638A patent/PH12020500638A1/en unknown
- 2020-08-24 IL IL276887A patent/IL276887B2/en unknown
- 2020-08-24 MX MX2023005716A patent/MX2023005716A/es unknown
- 2020-08-26 CO CONC2020/0010537A patent/CO2020010537A2/es unknown
-
2021
- 2021-04-26 US US17/240,041 patent/US11807633B2/en active Active
-
2023
- 2023-06-12 JP JP2023096315A patent/JP7521070B2/ja active Active
- 2023-09-21 US US18/471,594 patent/US12319675B2/en active Active
- 2023-11-24 ZA ZA2023/10843A patent/ZA202310843B/en unknown
- 2023-12-12 AU AU2023282201A patent/AU2023282201B2/en active Active
-
2024
- 2024-07-10 JP JP2024111017A patent/JP2024138421A/ja active Pending
-
2025
- 2025-05-01 US US19/196,040 patent/US20250346586A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021514007A5 (https=) | ||
| JP2023110094A5 (https=) | ||
| JP2022509260A5 (https=) | ||
| IL276887B2 (en) | Novel chromium as inhibitors of tcr–nck interaction | |
| KR960014126A (ko) | 시클로알카노-인돌 및 -아자인돌 유도체 | |
| JP2018519302A5 (https=) | ||
| PT672042E (pt) | Derivados de pirimidinoamina farmacologicamente activos e processos para a sua preparacao | |
| JPS6232185B2 (https=) | ||
| HUE034983T2 (en) | N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamides and n-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamides and their therapeutic use | |
| JP6505095B2 (ja) | Ｔｃｒ−ｎｃｋ相互作用の阻害剤としての、アルコキシドによって置換されたクロメン誘導体 | |
| JPS61218537A (ja) | フルオロケミカル組成物 | |
| US2231363A (en) | Preparation of alpha-chloracrylonitrile | |
| BR8203746A (pt) | Composicao acaricida uso e processo para sua producao | |
| JPH0297548A (ja) | フッ素ゴム加硫用組成物 | |
| CN118510502A (zh) | Akt3调节剂 | |
| US2544296A (en) | 1-(p-tolylthio)-3-trimethylsilyl-propane | |
| FR452503A (fr) | Perfectionnements dans la fabrication des dérivés di-chlorés d'hydrocarbures ayant les atomes de chlore liés à différents atomes de carbone | |
| FR17010E (fr) | Perfectionnements dans la fabrication des dérivés di-chlorés d'hydrocarbures ayant les atomes de chlore liés à différents atomes de carbone | |
| Le Brun | PORTRAIT OF HERSELF | |
| GB890425A (en) | Improvements in or relating to processes for producing fluorinated compounds and products obtained thereby | |
| Adler | B-CLL IS A CONDITION OF AGING: AN EDITORIAL COMMENT | |
| Stump et al. | Synthesis of Perfluorosuccinodithionamide and Perfluoroadipodithionamide. | |
| FR458556A (fr) | Procédé pour la préparation de la pate boulangère | |
| FR461223A (fr) | Procédé de préparation d'éthers-sels et d'éthers-oxydes de l'éthylidène-glycol et de l'alcool vinylique | |
| FR460571A (fr) | Procédé pour la préparation du 2.4.6.21.41.61.-hexanitrodiphenylsulfite et son emploi à la fabrication d'explosifs |